Cincinnati – September 15, 2026 -- Food Allergy Research & Education (FARE) has launched Anatool, a digital clinical support tool designed to standardize anaphylaxis recognition and treatment at the point of care for emergency physicians, paramedics, nurses and allergists.
Tool translates international consensus report into bedside guidance
Developed with Tim Dribin, MD, of the Division of Emergency Medicine at Cincinnati Children's, Anatool is built on recommendations from a landmark international consensus report on anaphylaxis published in The Journal of Allergy and Clinical Immunology. Dribin co-chaired that report with Hugh Sampson, MD, of the Icahn School of Medicine at Mount Sinai, and Antonella Muraro, PhD, of the University of Padua.
Dribin said clinicians and healthcare systems have historically relied on differing definitions and treatment approaches for anaphylaxis, delaying epinephrine administration even when patients meet treatment criteria. Anatool is intended to give providers a single, evidence-based framework at the bedside.
Tool incorporates infant-specific criteria for the first time
Anatool is the first clinical resource to integrate infant-specific findings into anaphylaxis assessment and management, addressing a gap for providers who do not routinely treat pediatric patients. The tool also updates diagnostic criteria and provides guidance on intramuscular epinephrine and intranasal epinephrine (neffy), the first FDA-approved needle-free epinephrine treatment for anaphylaxis.
Research shows epinephrine remains underused before hospital arrival
Studies led by Dribin have found that epinephrine is often underused in pre-hospital settings, while other research indicates many children receiving epinephrine could be safely discharged sooner than current observation practices allow.
FARE CEO Sung Poblete, PhD, RN, noted that food allergy affects 1 in 10 adults in the U.S., underscoring demand for tools that speed clinical decision-making during severe allergic reactions.
Anatool was one of several new resources FARE announced during the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting and is available to healthcare professionals through FARE's dedicated platform.